In particular, patients with the KIT exon 11 deletion mutation benefit most from the longer duration of adjuvant imatinib, while patients with the kit exon 9 mutation could benefit more from adjuvant imatinib with 800 mg/day dose (based on activity data in patients with advanced GIST in this specific genotype). Here, KIT is linked to gastrointestinal stromal tumor.